Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Articles

Patients with inflammatory bowel disease who underwent a switch from reference infliximab to a biosimilar and then back to the originator were more likely to discontinue their treatment than patients who underwent a single switch from the originator to a biosimilar.

Study: Multiple Switches Between Infliximab Products May Lead to Higher Rates of Treatment Discontinuation

Drug maker payments to ophthalmologists were associated with the choice of higher-cost therapies for age-related macular degeneration (ARMD) that could increase Medicare, but biosimilars could help.

Higher-Cost Therapies for ARMD Could Contribute to Heightened Medicare Costs; Biosimilars Could Help

Gillian is an assistant editor for Pharmacy Times®.

The House Committee members examined pricing tactics by PBMs and how they are harming patients across the country.

House Committee Hearing Addresses PBMs, Anticompetitive Drug Pricing Tactics

Videos

Here are the top 5 biosimilar articles for the week of September 18, 2023.

The Top 5 Biosimilar Articles for the Week of September 18

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

The Role of Biosimilars in Oncology

Available Oncology Biosimilars and Their Efficacy

What Are Biosimilars?

Are Biosimilars and Biologics Similar?

Can Biosimilars Be Switched?

The FDA Approval of Biosimilars 

The FDA Pathway for Interchangeable Biosimilars

Deciding Which Biosimilar to Use

How Biosimilars Have Impacted Cancer Treatment

Patient Access to Biosimilars

The Economic Impact of Biosimilars

The Role of Insurance Companies and PBMs on Biosimilar Access

Formulary Inclusion for Biosimilars

Biosimilar Challenges for Providers and Payers

Educating Patients and Clinicians About Biosimilars